A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
6d
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback